{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T05:16:33Z","timestamp":1733289393500,"version":"3.30.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00393-024-01563-2","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T09:30:48Z","timestamp":1727170248000},"page":"812-821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neues zur Therapie von Gro\u00dfgef\u00e4\u00dfvaskulitiden","News on the treatment of large vessel vasculitis"],"prefix":"10.1007","volume":"83","author":[{"given":"Nils","family":"Venhoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Zeisbrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"1563_CR1","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","volume":"58","author":"S Adler","year":"2019","unstructured":"Adler\u00a0S, Reichenbach\u00a0S, Gloor\u00a0A et\u00a0al (2019) Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology 58:1639\u20131643","journal-title":"Rheumatology"},{"key":"1563_CR2","doi-asserted-by":"publisher","first-page":"e619","DOI":"10.1016\/S2665-9913(21)00152-1","volume":"3","author":"L Christ","year":"2021","unstructured":"Christ\u00a0L, Seitz\u00a0L, Scholz\u00a0G et\u00a0al (2021) Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a\u00a0single-arm, open-label, proof-of-concept study. Lancet Rheumatol 3:e619\u2013e626","journal-title":"Lancet Rheumatol"},{"key":"1563_CR3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","volume":"81","author":"MC Cid","year":"2022","unstructured":"Cid\u00a0MC, Unizony\u00a0SH, Blockmans\u00a0D et\u00a0al (2022) Efficacy and safety of mavrilimumab in giant cell arteritis: a\u00a0phase\u00a02, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81:653\u2013661","journal-title":"Ann Rheum Dis"},{"key":"1563_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.semarthrit.2018.04.004","volume":"48","author":"R Conway","year":"2018","unstructured":"Conway\u00a0R, O\u2019neill\u00a0L, Gallagher\u00a0P et\u00a0al (2018) Ustekinumab for refractory giant cell arteritis: A\u00a0prospective 52-week trial. Semin Arthritis Rheum 48:523\u2013528","journal-title":"Semin Arthritis Rheum"},{"key":"1563_CR5","doi-asserted-by":"crossref","unstructured":"Blockmans D, Penn SK, Setty A et al (2024) Abstract LBA0001 Efficacy and safety of Upadacitinib in patients with giant cell arteritis (SELECTGCA): A double-blind, randomized controlled phase 3 trial. Ann Rheum Dis 83:232\u2013233","DOI":"10.1136\/annrheumdis-2024-eular.LBA25"},{"key":"1563_CR6","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/mr\/roac099","volume":"33","author":"M Harigai","year":"2023","unstructured":"Harigai\u00a0M, Miyamae\u00a0T, Hashimoto\u00a0H et\u00a0al (2023) A multicentre, large-scale, observational study of tocilizumab in patients with Takayasu arteritis in Japan: The ACTEMRA\u00ae (ACT)-Bridge study. Mod Rheumatol 33:998\u20131006","journal-title":"Mod Rheumatol"},{"key":"1563_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich\u00a0B, Agueda\u00a0A, Monti\u00a0S et\u00a0al (2020) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79:19\u201330","journal-title":"Ann Rheum Dis"},{"key":"1563_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","volume":"146","author":"GS Hoffman","year":"2007","unstructured":"Hoffman\u00a0GS, Cid\u00a0MC, Rendt-Zagar\u00a0KE et\u00a0al (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a\u00a0randomized trial. Ann Intern Med 146:621\u2013630","journal-title":"Ann Intern Med"},{"key":"1563_CR9","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1002\/art.20300","volume":"50","author":"GS Hoffman","year":"2004","unstructured":"Hoffman\u00a0GS, Merkel\u00a0PA, Brasington\u00a0RD et\u00a0al (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50:2296\u20132304","journal-title":"Arthritis Rheum"},{"key":"1563_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/annrheumdis-2021-220832","volume":"81","author":"X Kong","year":"2022","unstructured":"Kong\u00a0X, Sun\u00a0Y, Dai\u00a0X et\u00a0al (2022) Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a\u00a0prospective observational study. Ann Rheum Dis 81:117\u2013123","journal-title":"Ann Rheum Dis"},{"key":"1563_CR11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/annrheumdis-2021-221961","volume":"81","author":"MJ Koster","year":"2022","unstructured":"Koster\u00a0MJ, Crowson\u00a0CS, Giblon\u00a0RE et\u00a0al (2022) Baricitinib for relapsing giant cell arteritis: a\u00a0prospective open-label 52-week pilot study. Ann Rheum Dis 81:861\u2013867","journal-title":"Ann Rheum Dis"},{"key":"1563_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13063-024-07905-4","volume":"25","author":"L Kreis","year":"2024","unstructured":"Kreis\u00a0L, Dejaco\u00a0C, Schmidt\u00a0WA et\u00a0al (2024) The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a\u00a0randomized, double-blind, placebo-controlled, parallel-group phase\u00a0II study. Trials 25:56","journal-title":"Trials"},{"key":"1563_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford\u00a0CA, Cuthbertson\u00a0D, Ytterberg\u00a0SR et\u00a0al (2017) A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol 69:837\u2013845","journal-title":"Arthritis Rheumatol"},{"key":"1563_CR14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40037","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford\u00a0CA, Cuthbertson\u00a0D, Ytterberg\u00a0SR et\u00a0al (2017) A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis Rheumatol 69:846\u2013853","journal-title":"Arthritis Rheumatol"},{"key":"1563_CR15","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/art.22754","volume":"56","author":"AD Mahr","year":"2007","unstructured":"Mahr\u00a0AD, Jover\u00a0JA, Spiera\u00a0RF et\u00a0al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56:2789\u20132797","journal-title":"Arthritis Rheum"},{"key":"1563_CR16","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/modpathol.2017.10","volume":"30","author":"JJ Maleszewski","year":"2017","unstructured":"Maleszewski\u00a0JJ, Younge\u00a0BR, Fritzlen\u00a0JT et\u00a0al (2017) Clinical and pathological evolution of giant cell arteritis: a\u00a0prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod Pathol 30:788\u2013796","journal-title":"Mod Pathol"},{"key":"1563_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/ard.2007.082115","volume":"67","author":"VM Mart\u00ednez-Taboada","year":"2008","unstructured":"Mart\u00ednez-Taboada\u00a0VM, Rodr\u00edguez-Valverde\u00a0V, Carre\u00f1o\u00a0L et\u00a0al (2008) A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 67:625\u2013630","journal-title":"Ann Rheum Dis"},{"key":"1563_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/acr.24200","volume":"73","author":"MA Matza","year":"2021","unstructured":"Matza\u00a0MA, Fernandes\u00a0AD, Stone\u00a0JH et\u00a0al (2021) Ustekinumab for the Treatment of Giant Cell Arteritis. Arthritis Care Res 73:893\u2013897","journal-title":"Arthritis Care Res"},{"key":"1563_CR19","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/art.41774","volume":"73","author":"M Maz","year":"2021","unstructured":"Maz\u00a0M, Chung\u00a0SA, Abril\u00a0A et\u00a0al (2021) 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol 73:1349\u20131365","journal-title":"Arthritis Rheumatol"},{"key":"1563_CR20","doi-asserted-by":"crossref","unstructured":"Mensch N, Hemmig AK, Aschwanden M et\u00a0al (2023) Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a\u00a0single centre cohort study. RMD Open 9:","DOI":"10.1136\/rmdopen-2023-003301"},{"key":"1563_CR21","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s00296-021-04958-5","volume":"41","author":"DP Misra","year":"2021","unstructured":"Misra\u00a0DP, Rathore\u00a0U, Patro\u00a0P et\u00a0al (2021) Corticosteroid monotherapy for the management of Takayasu arteritis\u2013a systematic review and meta-analysis. Rheumatol Int 41:1729\u20131742","journal-title":"Rheumatol Int"},{"key":"1563_CR22","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1007\/s10067-021-05743-2","volume":"40","author":"DP Misra","year":"2021","unstructured":"Misra\u00a0DP, Rathore\u00a0U, Patro\u00a0P et\u00a0al (2021) Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis\u2013a systematic review and meta-analysis. Clin Rheumatol 40:4391\u20134416","journal-title":"Clin Rheumatol"},{"key":"1563_CR23","doi-asserted-by":"publisher","first-page":"103275","DOI":"10.1016\/j.autrev.2023.103275","volume":"22","author":"DP Misra","year":"2023","unstructured":"Misra\u00a0DP, Singh\u00a0K, Rathore\u00a0U et\u00a0al (2023) The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu Arteritis: A\u00a0systematic review and meta-analysis. Autoimmun Rev 22:103275","journal-title":"Autoimmun Rev"},{"key":"1563_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/rheumatology\/kead215","volume":"63","author":"F Muratore","year":"2024","unstructured":"Muratore\u00a0F, Marvisi\u00a0C, Cassone\u00a0G et\u00a0al (2024) Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a\u00a0prospective observational study. Rheumatology 63:64\u201371","journal-title":"Rheumatology"},{"key":"1563_CR25","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","volume":"77","author":"Y Nakaoka","year":"2018","unstructured":"Nakaoka\u00a0Y, Isobe\u00a0M, Takei\u00a0S et\u00a0al (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a\u00a0randomised, double-blind, placebo-controlled, phase\u00a03\u00a0trial in Japan (the TAKT study). Ann Rheum Dis 77:348\u2013354","journal-title":"Ann Rheum Dis"},{"key":"1563_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00393-020-00893-1","volume":"79","author":"JH Schirmer","year":"2020","unstructured":"Schirmer\u00a0JH, Aries\u00a0PM, Balzer\u00a0K et\u00a0al (2020) S2k guidelines: management of large-vessel vasculitis. Z\u00a0Rheumatol 79:67\u201395","journal-title":"Z Rheumatol"},{"key":"1563_CR27","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/art.39596","volume":"68","author":"J Schmidt","year":"2016","unstructured":"Schmidt\u00a0J, Smail\u00a0A, Roche\u00a0B et\u00a0al (2016) Incidence of Severe Infections and Infection-Related Mortality During the Course of Giant Cell Arteritis: A\u00a0Multicenter, Prospective, Double-Cohort Study. Arthritis Rheumatol 68:1477\u20131482","journal-title":"Arthritis Rheumatol"},{"key":"1563_CR28","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40744-020-00227-2","volume":"7","author":"WA Schmidt","year":"2020","unstructured":"Schmidt\u00a0WA, Dasgupta\u00a0B, Luqmani\u00a0R et\u00a0al (2020) A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis. Rheumatol Ther 7:793\u2013810","journal-title":"Rheumatol Ther"},{"key":"1563_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13075-023-03177-6","volume":"25","author":"WA Schmidt","year":"2023","unstructured":"Schmidt\u00a0WA, Dasgupta\u00a0B, Sloane\u00a0J et\u00a0al (2023) A phase\u00a03 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis. Arthritis Res Ther 25:199","journal-title":"Arthritis Res Ther"},{"key":"1563_CR30","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","volume":"73","author":"R Seror","year":"2014","unstructured":"Seror\u00a0R, Baron\u00a0G, Hachulla\u00a0E et\u00a0al (2014) Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a\u00a0multicentre randomised controlled trial. Ann Rheum Dis 73:2074\u20132081","journal-title":"Ann Rheum Dis"},{"key":"1563_CR31","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S2665-9913(21)00038-2","volume":"3","author":"JH Stone","year":"2021","unstructured":"Stone\u00a0JH, Han\u00a0J, Aringer\u00a0M et\u00a0al (2021) Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatol 3:e328\u2013e336","journal-title":"Lancet Rheumatol"},{"key":"1563_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone\u00a0JH, Tuckwell\u00a0K, Dimonaco\u00a0S et\u00a0al (2017) Trial of Tocilizumab in Giant-Cell Arteritis. N\u00a0Engl J Med 377:317\u2013328","journal-title":"N Engl J Med"},{"key":"1563_CR33","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/art.42496","volume":"75","author":"X Tian","year":"2023","unstructured":"Tian\u00a0X, Li\u00a0M, Jiang\u00a0N et\u00a0al (2023) Comparative Efficacy of Secukinumab Versus Tumor Necrosis Factor Inhibitors for the Treatment of Takayasu Arteritis. Arthritis Rheumatol 75:1415\u20131423","journal-title":"Arthritis Rheumatol"},{"key":"1563_CR34","doi-asserted-by":"crossref","unstructured":"Tomelleri A, Dejaco C (2024) New blood biomarkers and imaging for disease stratification and monitoring of giant cell arteritis. RMD Open 10:","DOI":"10.1136\/rmdopen-2023-003397"},{"key":"1563_CR35","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","volume":"5","author":"N Venhoff","year":"2023","unstructured":"Venhoff\u00a0N, Schmidt\u00a0WA, Bergner\u00a0R et\u00a0al (2023) Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a\u00a0randomised, double-blind, placebo-controlled, phase\u00a02\u00a0trial. Lancet Rheumatol 5:e341\u2013e350","journal-title":"Lancet Rheumatol"},{"key":"1563_CR36","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger\u00a0PM, Adler\u00a0S, Kuchen\u00a0S et\u00a0al (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a\u00a0phase\u00a02, randomised, double-blind, placebo-controlled trial. Lancet 387:1921\u20131927","journal-title":"Lancet"},{"key":"1563_CR37","doi-asserted-by":"publisher","first-page":"152018","DOI":"10.1016\/j.semarthrit.2022.152018","volume":"55","author":"J Wang","year":"2022","unstructured":"Wang\u00a0J, Dai\u00a0X, Ma\u00a0L et\u00a0al (2022) Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A\u00a0prospective study. Semin Arthritis Rheum 55:152018","journal-title":"Semin Arthritis Rheum"},{"key":"1563_CR38","doi-asserted-by":"publisher","first-page":"1199059","DOI":"10.3389\/fimmu.2023.1199059","volume":"14","author":"M Zeisbrich","year":"2023","unstructured":"Zeisbrich\u00a0M, Thiel\u00a0J, Venhoff\u00a0N (2023) The IL-17 pathway as a\u00a0target in giant cell arteritis. Front Immunol 14:1199059","journal-title":"Front Immunol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01563-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01563-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01563-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T07:03:28Z","timestamp":1733209408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01563-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1563"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01563-2","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2024,9,20]]},"assertion":[{"value":"27 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.\u00a0Venhoff: Als Referent t\u00e4tig f\u00fcr AbbVie, AstraZeneca, BMS, Boehringer-Ingelheim, Chugai, Celgene, GSK, Novartis, Pfizer, Janssen, Roche, UCB, Vifor; Beraterhonorare von AbbVie, AstraZeneca, Boehringer-Ingelheim, GSK, Novartis, Pfizer, Janssen, Roche, UCB, Vifor; Forschungsgelder von AbbVie, Medac, Novartis, Pfizer; genannt als Erfinder auf einem Patentantrag der Firma Novartis und der Universit\u00e4tsklinik Freiburg zur Behandlung der Riesenzellarteriitis mit Secukinumab. M.\u00a0Zeisbrich gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}